approval · primary record
AMIVANTAMAB AND HYALURONIDASE-LPUJ
FDA · BLA · 2025-12-17
| Agency | FDA |
|---|---|
| Submission type | BLA |
| Action date | 2025-12-17 |
| Brand | RYBREVANT FASPRO |
| Sponsor | JANSSEN BIOTECH |
| Route | Not stated |
Provenance
- Source: openFDA Drugs@FDA
- Fetched at: 2026-10-28T03:31:08.092Z
- Licence class: public-domain
- Verdict: primary-source
- Entity id: FDA:AMIVANTAMAB AND HYALURONIDASE-LPUJ:2025-12-17
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.